NEO
Neogenomics·NASDAQ
--
--(--)
--
--(--)
NEO fundamentals
Neogenomics (NEO) released its earnings on Feb 17, 2026: revenue was 190.17M (YoY +10.56%), beat estimates; EPS was 0.06 (YoY +50.00%), beat estimates.
Revenue / YoY
190.17M
+10.56%
EPS / YoY
0.06
+50.00%
Report date
Feb 17, 2026
NEO Earnings Call Summary for Q4,2025
- Revenue Growth: Q4 2025 revenue up 11% YoY to $190 million, with clinical revenue growing 16% YoY. Full-year revenue rose 10% to $727 million.
- NGS Momentum: NGS revenue grew 23% YoY in Q4, driven by higher-value tests and AUP expansion. PanTracer Pro and potential LBx approval could accelerate growth.
- MRD Expansion: RaDaR ST launched in February 2026 with 25 new sales reps targeting head and neck cancer. Additional MolDx submissions aim to double addressable market.
- Financial Health: 2026 guidance includes 10% revenue growth and 27%-31% EBITDA expansion, supported by gross margin improvements.
- Strategic Investments: $160 million in cash, with focus on R&D, sales force expansion, and LIMS integration for long-term efficiency gains.
EPS
Actual | -0.02 | -0.04 | 0.06 | 0.14 | -0.04 | -0.01 | -0.08 | -0.14 | -0.2 | -0.16 | -0.14 | -0.06 | -0.09 | -0.05 | 0 | 0.03 | -0.02 | 0.03 | 0.05 | 0.04 | 0 | 0.03 | 0.03 | 0.06 | ||||||||||
Forecast | 0.0188 | -0.1038 | 0.038 | 0.0597 | 0.0089 | -0.0133 | -0.09 | -0.1509 | -0.2376 | -0.2345 | -0.2062 | -0.1646 | -0.1394 | -0.1141 | -0.0746 | -0.0247 | -0.0397 | -0.0031 | 0.0123 | 0.0288 | -0.0131 | 0.0232 | 0.0205 | 0.0406 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -206.38% | +61.46% | +57.89% | +134.51% | -549.44% | +24.81% | +11.11% | +7.22% | +15.82% | +31.77% | +32.10% | +63.55% | +35.44% | +56.18% | +100.00% | +221.46% | +49.62% | +1067.74% | +306.50% | +38.89% | +100.00% | +29.31% | +46.34% | +47.78% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 106.03M | 86.98M | 125.44M | 126.00M | 115.53M | 121.72M | 121.34M | 125.73M | 117.17M | 125.07M | 128.78M | 138.71M | 137.22M | 146.92M | 151.95M | 155.55M | 156.24M | 164.50M | 167.82M | 172.00M | 168.03M | 181.33M | 187.80M | 190.17M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 105.24M | 86.55M | 126.22M | 123.65M | 112.14M | 121.47M | 124.56M | 125.74M | 116.71M | 122.93M | 121.54M | 129.97M | 129.27M | 137.45M | 141.67M | 152.54M | 149.85M | 161.82M | 167.00M | 173.19M | 170.58M | 182.65M | 183.73M | 188.60M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +0.76% | +0.49% | -0.62% | +1.90% | +3.02% | +0.21% | -2.59% | -0.01% | +0.39% | +1.74% | +5.96% | +6.72% | +6.15% | +6.89% | +7.26% | +1.97% | +4.26% | +1.66% | +0.49% | -0.69% | -1.49% | -0.72% | +2.22% | +0.83% |
Earnings Call
You can ask Aime
What were the key takeaways from Neogenomics's earnings call?What guidance did Neogenomics's management provide for the next earnings period?What is Neogenomics's gross profit margin?What is the revenue and EPS growth rate for Neogenomics year over year?What does Neogenomics do and what are its main business segments?What is the market's earnings forecast for Neogenomics next quarter?Did Neogenomics beat or miss consensus estimates last quarter?What factors drove the changes in Neogenomics's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
